BerGenBio
BerGenBio, merged into Oncoinvent ASA in October 2025, is a Norwegian clinical-stage biotech developing Radspherin, a receptor-independent alpha-emitting radiopharmaceutical designed to eradicate residual cancer cells in the abdominal cavity after surgery, with lead programs in peritoneal metastases from ovarian and colorectal cancers.
- Company typePublic
- Founded2007
- HeadquartersBergen, Norway
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BerGenBio does
BerGenBio was a Norwegian clinical-stage biopharmaceutical company founded in 2007 and listed on the Oslo Stock Exchange under ticker BGBIO. Its original therapeutic focus was first-in-class selective AXL kinase inhibitors targeting treatment-resistant aggressive cancers. On October 29, 2025, BerGenBio completed a merger with Oncoinvent ASA, financed by an oversubscribed NOK 130 million rights issue; the combined entity was renamed Oncoinvent ASA and trades under ticker ONCIN on Oslo Børs. The legacy AXL program remains part of the portfolio, but the merged company's strategic center of gravity has shifted to Radspherin, a receptor-independent alpha-emitting radiopharmaceutical designed to eradicate residual cancer cells in the abdominal cavity after surgery with a single targeted dose at a recommended 7MBq level.
Radspherin is being developed primarily for peritoneal metastases from ovarian cancer (currently in a multi-country Phase 2 trial with 54 of a planned ~108 patients enrolled across 10 sites in the US, Spain, Norway, Belgium, UK, and Italy) and is also being evaluated in a Phase 1/2a trial in colorectal cancer. The technology platform rests on a proprietary size-controlled calcium carbonate microparticle carrier, protected by a composition-of-matter patent valid until 2035 (2036 in some jurisdictions) and a new CNIPA-granted patent extending coverage in China to 2041. Positive final Phase 1 data in ovarian cancer with 24-month follow-up were presented at the ESGO 2026 Congress, and no dose-limiting toxicity has been observed at the recommended dose.
The company is pre-revenue with no commercialized products, deriving no recurring license or product revenue today. Its go-to-market, once Radspherin is approved, is planned to run through hospital pharmacies and specialized oncology treatment centers. Marketing activity to date has been limited to investor relations, healthcare conference participation (DNB Nordic, H.C. Wainwright, Arctic Securities, Carnegie), and peer-reviewed publications in journals such as Gynecologic Oncology, Journal of Surgical Oncology, and Frontiers in Medicine. Leadership post-merger comprises CEO Øystein Soug, CFO Dr Ramzi Amri, and Chair Gillies O'Bryan-Tear, supported by a full board and audit, remuneration, and nomination committees. The company is headquartered at Gullhaugveien 7, 0484 Oslo, Norway.
BerGenBio firmographics
Firmographics- Name
- BerGenBio
- Legal name
- BerGenBio, AS.
- Website
- https://bergenbio.com
- Company type
- Public
- Founded year
- 2007
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- BerGenBio, merged into Oncoinvent ASA in October 2025, is a Norwegian clinical-stage biotech developing Radspherin, a receptor-independent alpha-emitting radiopharmaceutical designed to eradicate residual cancer cells in the abdominal cavity after surgery, with lead programs in peritoneal metastases from ovarian and colorectal cancers.
- Ownership category
- akta.pro rank
BerGenBio industry classification
Industry- Product category
- Clinical-Stage Oncology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
- akta.pro secondary industry
- Medical Oncology (HLAKAFAB)
Keywords
Where BerGenBio is headquartered
LocationHeadquarters
- HQ city
- Bergen
- HQ country
- Norway
- HQ region
- Europe
Offices1 record
Markets served
BerGenBio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pre-commercial / Product Revenue (Future): BerGenBio was a clinical-stage biotech company. The merger with Oncoinvent combined pipelines to develop Radspherin® for abdominal cavity cancer treatment. No commercial revenue currently as products are in clinical trials.
Distribution channels1 record
Marketing channels3 records
BerGenBio product offering
Product offeringCore offering
BerGenBio ASA is a clinical-stage biopharmaceutical company developing selective AXL kinase inhibitors and other targeted oncology therapeutics for aggressive cancers, including non-small cell lung cancer and COVID-19. Following its October 2025 merger with Oncoinvent ASA, the combined entity (renamed Oncoinvent ASA) is focused on advancing Radspherin®, an alpha-emitting radiopharmaceutical therapy designed to eradicate residual cancer cells in the abdominal cavity after surgery.
Product overview
BerGenBio was a biotech company developing first-in-class AXL inhibitors for aggressive diseases, including treatment-resistant cancers. Following the merger with Oncoinvent ASA completed on October 29, 2025, the combined entity was renamed Oncoinvent ASA. The merged company's lead product is Radspherin, a receptor-independent alpha radiopharmaceutical for eradicating cancer cells in the abdominal cavity after surgery with a single targeted dose. The product portfolio includes Radspherin for abdominal cavity cancer treatment (ovarian and colorectal cancers) and the legacy AXL inhibitor program from BerGenBio.
Differentiator
Problem solved
Functional benefit
Products and services
- Radspherin® Alpha-emitting radiopharmaceutical therapy administered as a single targeted dose designed to eradicate cancer cells in the abdominal cavity after surgery. Developed by Oncoinvent and now the lead clinical asset of the merged company, targeting peritoneal metastases from cancers such as ovarian and colorectal.
- Bemcentinib Selective AXL kinase inhibitor developed by BerGenBio and evaluated in Phase 2 clinical trials, including as a first-line treatment in combination with pembrolizumab and chemotherapy in non-squamous non-small cell lung cancer (NSCLC) patients, and in COVID-19 studies.
- Tilvestamab
Quantifiable outcome
- No dose-limiting toxicity observed at recommended dose of 7MBq
- +1 more outcomes
Companies that use BerGenBio
Customer profileSegments2 records
Ideal customer profiles2 records
BerGenBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
BerGenBio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Oncoinvent ASAflagshipBerGenBio announced merger agreement to acquire Oncoinvent ASA, a Norwegian biotech company developing Radspherin® for abdominal cavity cancer treatment. The combined entity planned a fully underwritten rights issue. Merger completed October 29, 2025, with combined entity renamed to Oncoinvent ASA.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
BerGenBio competitors and assessment
Company assessmentMarket position
Competitive moat2 records
Key risks6 records
Key highlights7 records
Customer concentration
BerGenBio social profiles
Digital presenceBerGenBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
BerGenBio leadership team
Management profileNumber of profiles
Profiles14 records
BerGenBio funding detail
Funding detailFunding overview
Funding rounds10 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BerGenBio M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BerGenBio
What does BerGenBio do?
BerGenBio ASA is a clinical-stage biopharmaceutical company developing selective AXL kinase inhibitors and other targeted oncology therapeutics for aggressive cancers, including non-small cell lung cancer and COVID-19. Following its October 2025 merger with Oncoinvent ASA, the combined entity (renamed Oncoinvent ASA) is focused on advancing Radspherin®, an alpha-emitting radiopharmaceutical therapy designed to eradicate residual cancer cells in the abdominal cavity after surgery.
Is BerGenBio a public or private company?
BerGenBio is a public company. It is classified as public and is currently acquired.
When was BerGenBio founded?
BerGenBio was founded in 2007. It employs 11 to 50 people.
Where is BerGenBio based?
BerGenBio is headquartered in Bergen, Norway, in the Europe region.
How does BerGenBio make money?
One revenue line is on record: pre-commercial / Product Revenue (Future).
Does BerGenBio have an API?
No public API is recorded for BerGenBio.
What industry is BerGenBio in?
BerGenBio's product category is Clinical-Stage Oncology Therapeutics. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAKAFAB, Medical Oncology. Its NAICS code is 325414 and its SIC code is 2834.